Endotoxin pp 653-664 | Cite as

New Therapeutic Method Against Septic Shock — Removal of Endotoxin Using Extracorporeal Circulation

  • M. Kodama
  • K. Hanasawa
  • T. Tani
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 256)

Abstract

Polymyxin B has been shown to prevent endotoxin-induced mortality of mice and rabbits (9, 10), and to decrease the incidence of endotoxindisseminated intravascular coagulation (1). However, its use is limited only to oral or local administration because of its strong side effect on the central nervous system and the kidneys. Therefore, it cannot be used by intravenous injection for the therapy of endotoxemia. To solve problems, a new method of preparing polymyxin B by fixing it to an insoluble fiber was developed. We previously reported that polymyxin B would be covalently coupled to an insoluble fiber and could not be removed anymore by washing with isotonic saline (1, 3).

Keywords

Endotoxin Shock Insoluble Fiber Endotoxin Concentration Aortic Blood Pressure Endotoxin Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Corrigan, J. J. and Bell, B. M., 1917, Comparison between the polymyxins and gentamicin in preventing endotoxin-induced intravascular coagulation and leukopenia. Infect. Immun. 4: 563.Google Scholar
  2. 2.
    Dunn, D. L. and Ferguson, R. M., 1982, Immunotherapy of gram-negative bacterial sepsis: Enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Surgery 92: 212.PubMedGoogle Scholar
  3. 3.
    Hanasawa, K., Tani, T., Oka, T., Yoshioka, T., Endo, Y., Horisawa, M., Nakane, Y., Kodama, M., Teramoto, K. and Nishiumi, S., 1984, A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber, in: “Therapeutic apheresis: a critical look,” Y. Nose, P. S. Malchesky and J. W. Smith, eds., Cleveland: ISAO Press,: 167.Google Scholar
  4. 4.
    Kanoh, S., Yoshida, M., Kobayashi, T. and Ogawa, S., 1966, Studies on pyrogen (I). Jpn. J. Pharmacol. 62: 135.Google Scholar
  5. 5.
    Kodama, M., Oka, T., Tani, T. and Hanasawa, K., 1985, Therapeutic plasmapheresis for hepatic disorder in surgical patients new strategies for dealing with hyperbilirubinemia, endotoxemia and hemorrhagic disorder, in: “Current practice in therapeutic plasmaphoresis,” T. Hoshino, ed., Excerpta Medica, Amsterdam, p. 102.Google Scholar
  6. 6.
    Nolan, J. P., Mcdevitt, J. J. and Goldmann, G. S., 1975, Endotoxin binding by charged and uncharged resin. Proc. Soc. Exp. Biol. Med. 149: 766.PubMedCrossRefGoogle Scholar
  7. 7.
    Obayashi, T., 1984, Addition of perchloric acid to blood samples for colorimetric limulus test using chromogenic substrate: Comparison with conventional procedures and clinical applications. J. Lab. Clin. Med. 104: 321.PubMedGoogle Scholar
  8. 8.
    Pineda, A. A. and Taswell, H. F., 1981, Selective plasma component removal: alternatives to plasma exchange. Artif Organs 5: 234.PubMedCrossRefGoogle Scholar
  9. 9.
    Rifkind, D., 1967, Prevention by polymyxin B of endotoxin lethality in mice. J. Bacteriol. 93: 1463.PubMedGoogle Scholar
  10. 10.
    Rifkind, D. and Hill, B. J., Rolla, 1967, Neutralization of the Shwartzman reactions by polymyxin B. J. Immunol. 99: 564.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • M. Kodama
    • 1
  • K. Hanasawa
    • 1
  • T. Tani
    • 1
  1. 1.Department of SurgeryShiga University of Medical ScienceSeta-Tsukiwacho, Otsu, ShigaJapan

Personalised recommendations